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ScienceDirectSince their discovery, bacteriophages have contributed
enormously to our understanding of molecular biology as
model systems. Furthermore, bacteriophages have provided
many tools that have advanced the fields of genetic
engineering and synthetic biology. Here, we discuss
bacteriophage-based technologies and their application to the
study of infectious diseases. New strategies for engineering
genomes have the potential to accelerate the design of novel
phages as therapies, diagnostics, and tools. Though almost a
century has elapsed since their discovery, bacteriophages
continue to have a major impact on modern biological
sciences, especially with the growth of multidrug-resistant
bacteria and interest in the microbiome.
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Background
With the discovery of bacteriophages generally being
credited to Frederick Twort [1] and Felix d’He´relle [2]
in the early 20th century, these virus particles were so
named (Greek, ‘bacteria eaters’) based on their observed
ability to lyse bacterial cells. The use of naturally occur-
ring phages as therapeutics for the treatment of bacterial
infections was quickly realized by d’He´relle and others,
with interest continuing to flourish until the discovery and
production of penicillin [2–4]. Antibiotics heralded a new
age of effective small molecule treatments for bacterial
infections, with phage therapy falling out of favor in thewww.sciencedirect.com Western World [5,6]. Though phages have remained an
important tool in the study of molecular biology, genetics,
and bacteria [7], concerns over the ever-dwindling arsenal
of antibiotics for the treatment of multidrug-resistant
bacterial pathogens have also resulted in a renaissance
in phage studies and in phage-based therapies as a means
to develop alternative therapeutics [8–11]. Correspond-
ingly, advances in synthetic biology have refined the
ability to design, modify, and synthesize these viruses,
which has enabled novel strategies for creating bacterio-
phage-based tools for the study and treatment of infec-
tious diseases. The goal of this review is to explore the
methods and demonstrations by which such tools can be
employed to engineer modified phage and phage parts.
For more information concerning the history, appli-
cations, and challenges of phage therapy using natural,
unmodified viruses, the reader is referred to other reviews
[12–15].
Synthetic biology aims to rationally engineer new func-
tionalities in living systems by co-opting and modifying
biomolecules crafted from millennia of evolution [16–18].
Cells operate as highly complex computational systems
able to dynamically interrogate and respond to their envi-
ronment. For the past decade, synthetic biologists have laid
the foundational rules of biological design [19], constructed
a catalog of standardized genetic parts, and assembled
simple circuits, such as oscillators [20], switches [21],
and Boolean logic gates [22,23]. Rational engineering
has yielded cellular devices able to produce potent anti-
malarial compounds [24], to detect and kill pathogenic
bacteria [25] and cancer cells [26], to reprogram cell fate
[27], and to treat metabolic syndrome [28]. Finally,
advancements in DNA synthesis and assembly have
enabled the rapid development of higher-order genetic
circuits [29–31] of medical [32] and industrial [33,34]
relevance. This field has been accelerated by phage-
derived technologies, while concomitantly enabling new
approaches to engineering phages themselves.
Phage-enabled technologies
Phage display
Described by Smith in 1985 [35], phage display is a
methodology employed extensively in both the study
of infectious diseases and the development of novel
therapeutics. Libraries comprising synthetic random pep-
tides or natural peptides derived from pathogen genomic
or cDNA are fused with a coat protein of a bacteriophage,
often M13, Fd, or l, such that the peptide is displayed on
the phage surface. Iterative selection steps are employedCurrent Opinion in Microbiology 2014, 19:59–69
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an immobilized target molecule of interest, which are
then eluted and propagated in Escherichia coli. Since the
identity of the displayed peptide is genetically encoded
in the phage genome, protein–ligand interactions can be
screened in high-throughput to identify molecules with
novel biological functions. Phage display has enabled the
discovery and characterization of bacterial adhesins
[36,37], which bind to receptors on host cells or extra-
cellular matrix and are implicated in establishing infec-
tion, as well as antigens used for vaccine development
[38]. Moreover, bioactive peptides that block anthrax
toxin binding [39] or inhibit cell wall biosynthesis
enzymes in Pseudomonas aeruginosa [40] were isolated
from phage display libraries. Development of antibody-
based therapeutics has also greatly benefited from the
technology, which can be implemented to rapidly screen
random libraries of antigen-binding domains [41]. In a
demonstration of direct therapeutic application, phage
particles selected for high affinity interaction to Staphy-
lococcus aureus were conjugated to chloramphenicol pro-
drugs to deliver localized, lethal payloads [42]. The
applications of phage display are vast and the reader is
referred to other literature [43–48] for a more thorough
discussion of additional examples.
Bacteriophage-derived parts for synthetic biology
Bacteriophages have formed the backbone of molecular
biology, having championed the demonstration of DNA
as genetic material [49], the proof of Darwinian natural
selection [50], and the ubiquitous use of phage-derived
enzymes for common laboratory protocols [51]. Similarly,
bacteriophage components constitute a core set of parts inFigure 1
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RNA polymerase of T7 can specifically drive high-level
transcription from the T7 promoter (PT7) both in vitro and
in vivo. The polymerase has been used to reconstitute in
vitro genetic circuits [52], such as switches [53] and
oscillators [54], which permit precise mathematical mod-
eling of biological reactions to inform future predictive
design. Moreover, libraries of orthogonal T7 and PT7
variants, which exhibit lower toxicity [55] or are split into
parts to function as AND gates [56] (Figure 1a and b),
have been constructed to permit higher-order construc-
tion of artificial genetic circuits. For example, an AND
gate that only outputs a Boolean TRUE value when both
inputs are TRUE can be implemented by having an
output gene that is only expressed when both parts of
a split T7 RNA polymerase are expressed. When coupled
with orthogonal ribosomes that do not translate host
mRNAs, a fully insulated transcription-translation net-
work was constructed in E. coli for protein expression [57].
Furthermore, bacteriophage recombinases have been
used in the construction of genetic circuits that record
memory of past reactions [58] (Figure 1c). Recombinases
manipulate DNA by recognizing specific sequences and
catalyzing the excision, integration, or inversion of DNA
segments depending on the location and orientation of
the recognition sites. Thus, recombinase expression is
coupled with a physical change in genetic material of the
cell that can be sequenced to assay exposure to past
events. The Cre, Bxb1, and PhiC31 recombinases have
been used in the construction of a variety of synthetic circuits
including counters [59], a rewritable memory module
[60], Boolean logic gates [22,23], and digital-to-analogOutput
Output
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al cells. (a) Truth table for AND gate function. An AND gate has a TRUE
t as a transcriptional AND gate. Inputs A and B, which can be exogenous
ression of the N-terminal and C-terminal halves of T7 RNA polymerase,
lymerase that can drive production of the output gene [56]. (c)
ate functionality with integrated memory. Recombinase activity leads to
. Activation of Bxb1 and PhiC31 leads to inversion of two unidirectional
gene [22].
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additional host factors, genetic circuits founded on their
activity could theoretically function in a wide range of
infectious hosts to permit recording of gene expression in
various environments.
Genome engineering
In addition to tools for classical molecular biology, phage-
derived enzymes and technologies have led to genome-
scale engineering techniques critical to the tailoring of
strains for specific applications. Recombineering is a
powerful technique that uses homologous recombination
to introduce highly targeted modifications, insertions, or
deletions to loci within cells. This technique has been
enabled through the transformation of DNA products
bearing flanking homology to target sequences in con-
junction with the highly active Red recombination system
from phage l. It has been applied toward modifications in
a variety of Gram-negative bacteria [61], including E. coli
[62], Salmonella enterica [63], Shigella flexneri [64], Vibrio
cholerae [65], Yersinia pestis [66], and P. aeruginosa [67].
A system with the potential for high-efficiency modifi-
cations in a large range of bacteria, including both Gram-
positive and Gram-negative examples, has recently been
described by combining broad-host mobile group II
introns, or ‘targetrons,’ with the widely used Cre/lox
recombination system from phage P1 [68]. This tech-
nique, known as Genome Editing via Targetrons and
Recombinases (GETR), involves first targeting introns
containing loxP-derived sites to a specific location in a
bacterial genome and subsequently using Cre recombi-
nase to catalyze recombination between loxP sites on the
chromosome and on a targeted construct. This technique
can be used to achieve insertions, deletions, inversions, or
even relocation of a chromosomal locus, depending on the
design of the sites and constructs. Mutations in the wild-
type loxP sequence allow for control of directionality of
recombination as well as the generation of orthogonal
sites permitting GETR to be used at multiple loci with-
out crosstalk [68,69].
Accelerating evolution
An important extension of genome-editing techniques
has been the development of multiplex automated gen-
ome engineering (MAGE), a technique for generating
genetic diversity through the iterative process of l-Red
protein b-mediated recombineering with a pool of short,
ssDNA oligonucleotides targeting a single or multiple
genomic loci. In the initial study published by Wang et al.
[70], MAGE was used to generate a mutant strain of E. coli
with increased production of lycopene using oligonucleo-
tides designed to simultaneously target 24 genetic com-
ponents. Automating the growth, transformation, and
recovery phases of the procedure has the potential to
enable hands-free rapid evolution of a population. Along
with specialized genome assembly techniques, MAGEwww.sciencedirect.com was used to recode all UAG stop codons from a strain of E.
coli in order to generate a free, customizable codon
(UAG), thus demonstrating the potential capacity to edit
the genetic code in engineered organisms [71,72]. MA-
GE presents additional opportunities as a tool for infec-
tious disease research by enabling the rapid optimization
of antimicrobial gene circuits or as a means for introducing
diversity into organisms and mapping out their evolution-
ary trajectories. Similarly, MAGE could be applied
toward evolving improved or even novel functions in
bacteriophages by diversifying key phage proteins, such
as host recognition elements.
Phage-assisted continuous evolution (PACE) as intro-
duced by Esvelt et al. [73] is another stride in accelerated
evolution enabled by phage-based technology. In PACE,
the life cycle of the filamentous phage M13 is linked with
an activity of interest to be evolved, which is used to drive
production of pIII, the minor coat protein required for
adsorption of infectious phage particles to the cognate
receptor on recipient cells (Figure 2). This technique was
first used to evolve T7 RNA polymerase variants with
new properties, such as the ability to recognize novel
promoter sequences, by replacing the gene encoding pIII
on the phage genome with the gene for T7 RNA poly-
merase and moving pIII expression under the control of a
target promoter on a heterologous plasmid. In this way, a
mutant T7 RNA polymerase with an improved ability to
initiate transcription from the target promoter results in
increased pIII production and a higher titer of infectious
phages. As with MAGE, the PACE platform enables
automated evolution, this time by maintaining productive
phage in continuous culture within a lagoon with a con-
stant inflow of fresh bacterial cells and an outflow ensur-
ing removal of non-propagative phage variants. PACE has
been used to explore how different parameters affect the
pathways of genotypic and phenotypic divergence and
convergence, contributing toward understanding how
evolution acts on single genes and potentially improving
the optimization of future engineering efforts [74,75].
Phage-enabled therapies and diagnostics
Antimicrobial phages
Rather than entirely redesigning or repurposing isolated
phages, some engineering efforts in synthetic biology
have been made toward adding functions or improving
existing phages. For example, Lu and Collins [76] incorp-
orated the gene encoding DspB, an enzyme that degrades
a polysaccharide adhesin implicated in biofilm formation,
into an engineered T7 phage. This modified phage
effectively cleared E. coli biofilms through cycles of in-
fection, phage-mediated lysis, and release of the recom-
binant dispersin enzyme to enzymatically degrade the
biofilm material itself and expose protected cells.
Additionally, the phage was modified to carry a gene
from phage T3 in order to expand its host range and
permit infection of the biofilm-forming strain used in theCurrent Opinion in Microbiology 2014, 19:59–69
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Phage-assisted continuous evolution. In phage-assisted continuous evolution (PACE), the protein activity of interest is linked to expression of the M13
coat protein pIII, which is required for binding and initiation of the phage infection cycle [73]. Within infected cells (top), the protein of interest is
expressed from the injected M13 genome and successful target activity drives expression of gene III on the accessory plasmid, permitting the
assembly of infectious phage progeny that can be further amplified and selected through subsequent rounds of infection (left). In the example shown
here, the protein of interest is T7 RNA polymerase (T7 RNAP), which can successfully drive production of gene III only if it recognizes the promoter that
controls gene III expression, thus enabling the evolution of T7 RNAP variants that can target new promoter sequences. If activity is insufficient to drive
expression of the coat protein, progeny will be non-infectious and fail to amplify. The target protein is evolved in a continuous fashion in the ‘lagoon’
(bottom), where the encoding infectious phages continually amplify via the input of fresh cells, while non-infectious particles fail to infect new cells and
are removed in the outflow.study. However, despite the promise of phage thera-
peutics, bacteria can display resistance toward phages
through innate means, such as restriction-modification
systems [77,78], as well as adaptive means, typified by
clustered regularly interspaced short palindromic repeats
(CRISPR)-CRISPR-associated (Cas) systems [79]. More-
over, mechanisms may emerge in a bacterial population
during the course of selective pressure by phages, in-
cluding phenotypic [80] and genotypic [81] causes of
decreased phage adsorption, among others [82]. These
hurdles may be tackled through the use of phage cocktails
[83], high-throughput phage evolution, or perhaps, givenCurrent Opinion in Microbiology 2014, 19:59–69 predictable evolutionary pathways, through the rational
engineering of phages [10].
In contrast to taking advantage of a phage’s natural ability
to lyse a target cell, some studies have focused on using
virus particles for their capacity to deliver nucleic acids to
target cells. Such an approach was taken by Westwater
et al. [84], in which the group utilized the non-lytic,
filamentous phage M13 to deliver specialized phagemid
DNA in place of the phage genome to target cells. The
engineered phagemids (plasmids carrying signals to
enable packaging into phage particles) were designedwww.sciencedirect.com
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destruction of target cells. Hagens and Bla¨si [85] also
applied this toxic payload concept using M13 to deliver
genes encoding the restriction enzyme BglII or the l S
holin to kill target E. coli by the introduction of double-
stranded breaks in the chromosome or the creation of
cytoplasmic membrane lesions, respectively. Sub-
sequently, delivery of BglII was used to rescue mice
infected with P. aeruginosa by adapting the system with
an engineered derivative of the P. aeruginosa filamentous
phage Pf3 [86]. These methods also resulted in a marked
decrease in release of endotoxin, one of the major con-
cerns with lytic phage therapy [15], as compared to killing
via lysis by a lytic phage [85,86]. More recently, M13-
derived particles were used to express a lethal mutant of
catabolite activator protein in E. coli O157:H7, a food-
borne pathogen that causes outbreaks of hemorrhagic
colitis [87]. Biotechnology companies have also begun
to make use of recombinant phage methods, such as virus-
like particles that deliver genes encoding small, acid-
soluble proteins to cause toxicity to target cells through
non-specific binding to DNA [88].Figure 3
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www.sciencedirect.com Phage-based delivery of antibiotic-sensitizing cassettes
Rather than encoding killing functions directly within
phage particles, Edgar et al. [89] used phage l as a chassis
to generate antibiotic-resensitizing particles through the
delivery of dominant wild-type copies of rpsL and gyrA
(Figure 3a). The transduction of these genes into target
cells resistant to streptomycin and fluoroquinolones, con-
ferred by mutations in rpsL and gyrA, respectively,
resulted in the production of wild-type enzymes suscept-
ible to the formerly ineffective drugs. In another demon-
stration, Lu and Collins [90] engineered M13 to carry
genes encoding transcription factors that modify the
native regulation of bacterial gene networks
(Figure 3b). Constructs encoding the LexA3 repressor
or SoxR regulator were used to disable the SOS response
and DNA repair or to modulate the response to oxidative
stress in target cells, respectively, thus potentiating the
toxic effects of antibiotic treatment and even resensitiz-
ing a resistant bacterial strain. A dual-function phage was
also created and validated by using M13 harboring the
global regulator csrA, to inhibit biofilm formation and the
associated increase in antibiotic resistance, and the porinM13
LexA3
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teriophage such as the temperate phage l (a) and the filamentous phage
y of dominant sensitive genes encoding wild-type enzymes such as gyrA
nce had previously been conferred by mutations in these genes [89]. (b)
ia, such as the SOS response normally induced in order to respond to
 inhibit the SOS response and resensitize cells to some antibiotics as well
Current Opinion in Microbiology 2014, 19:59–69
64 Novel technologies in microbiologyompF , to improve drug penetration. Examples such as
these demonstrate the capacity for bacteriophages to be
engineered as gene delivery devices in order to perturb
genetic networks in bacteria for both research and thera-
peutic applications. With this approach, one can alter a
gene network at a particular node and observe the qual-
itative and quantitative effects in order to better charac-
terize native regulatory systems. As models of the
interactions in complex regulatory webs of pathogens
grow increasingly robust, the ability to know which
strands to tug to elicit desired effects may enable ration-
ally designed novel therapeutics based on predictable
behaviors.
Genome mining for therapeutics
The development and improvement of next-generation
sequencing technology has enabled genomic and meta-
genomic analyses of phage populations [91,92]. For
example, sequencing of gut viral metagenomes has impli-
cated phages as reservoirs of antibiotic-resistance genes
[93] and their role in influencing the intestinal micro-
biota has been of recent interest [94]. Since bacterio-
phages must encode mechanisms to control their host
cells in order to infect, divert cellular resources to pro-
pagate, build progeny phages, and, in many cases, lyse
their hosts to release new particles, phage genomes con-
stitute a vast library of parts that can be used to manip-
ulate bacteria for study or treatment. On the basis of this
concept, Liu and colleagues [95] developed a method for
mining such tools to generate novel therapeutics against
S. aureus. Predicted phage open reading frames were
cloned with inducible expression into the target strain
and screened for growth-inhibitory properties. Identified
phage proteins were used to pull bacterial targets out of
cell lysates and a library of small molecules was screened
to identify inhibitors of the protein–protein interaction,
with the hypothesis that these molecules might demon-
strate similar modulatory action on the host target. In this
way, the authors identified novel compounds capable of
inhibiting the initiation of bacterial DNA replication in
analogy with the phage proteins. Since currently available
drugs that target replication only act on topoisomerases,
this work demonstrates that mining phage proteins long
evolved to inhibit bacterial processes has the potential to
expand the antibiotic repertoire by leading us to discover
drugs against previously unused targets [95,96].
In addition to random-discovery screens, phage lysins
have been specifically investigated in recent years as
potential antimicrobials. These enzymes are employed
by bacteriophages to degrade the bacterial cell wall and
permit the release of progeny phages [97]. In another
functional metagenomic study, phage DNA was isolated
from a mixture of feces from nine animal species, cloned
into a shotgun library for inducible expression in E. coli,
and used in primary and secondary screens to detect
lysins from the phage DNA pool [98]. As a discoveryCurrent Opinion in Microbiology 2014, 19:59–69 tool, a specific lysin from a phage of Bacillus anthracis
was used to develop a novel antimicrobial by identifying
an enzyme involved in the production of the lysin target
and designing a cognate chemical inhibitor [99]. Though
lysins are considered useful antimicrobials for Gram-
positive pathogens, Gram-negative bacteria possess an
outer membrane that prevents access of these extra-
cellular enzymes to the cell wall [100]. To overcome this
barrier, a chimeric protein composed of the translocation
domain of the Yersinia pestis bacteriocin, pesticin, and
the enzymatic domain of lysozyme from the E. coli
phage T4 was engineered. The hybrid bacteriocin
was shown to be active against E. coli and Y. pestis
strains, including those expressing the cognate immu-
nity protein conferring resistance to unmodified pesticin
[101,102].
Detection of pathogens
Bacteriophages have also been used to implement real-
world applications of biosensing [103–107]. In areas from
healthcare and hospital surfaces to food preparation and
other industrial processes, methods for the rapid detec-
tion of pathogenic organisms are paramount in preventing
disease and avoiding the public relations and financial
burdens of recalling contaminated products. The amount
of time necessary for many conventional detection
methods is long due to the requirement for bacterial
enrichment before detection of the few bacteria present
in complex samples in order to achieve sufficient assay
sensitivity and specificity [108]. Engineered bacterio-
phage-based detectors have the advantage of rapid read-
outs, high sensitivity and specificity, and detection of live
cells [109]. A common design strategy is the creation of
reporter-based constructs packaged within phage or
phage-like particles that infect target cells and ultimately
result in the production of fluorescent, colorimetric, or
luminescent signals. Furthermore, sensor designs can
include genetically engineered phage that express a pro-
duct causing ice nucleation [110] or that incorporate tags
for linking to detectable elements such as quantum dots
[111]. Though most of these examples of specifically
modified phages have been enabled by advancements
in engineering and synthetic biology to achieve real-world
applicability, the concept of using natural phage as sen-
sing tools is not a new one. Phage typing and other
techniques have made use of the narrow host range of
phage to identify species or strains of bacteria based on a
target bacteria’s ability to bind, propagate, or be lysed by
non-engineered viruses [109].
New phage engineering strategies
Historically, modifications to bacteriophage relied on
random mutagenesis or homologous recombination, both
of which are inefficient and necessitate intensive screen-
ing to identify mutants of interest. The relatively large
size of most bacteriophage genomes and their inherent
toxicity to bacterial hosts has confounded the use ofwww.sciencedirect.com
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Synergy between synthetic biology and bacteriophage. New tools and
techniques from synthetic biology have enabled phage research and the
development of novel therapies. Likewise, bacteriophage components
have fueled innovation in synthetic biology.conventional molecular biology techniques for engineer-
ing. However, recent synthetic biology tools have revi-
talized the ability to make rational additions or
modifications to phage genomes. Among such improve-
ments, the phage defense function encoded by CRISPR-
Cas systems, previously adapted for genome editing [112–
117] and reviewed in [118], has been described for
improving recombineering in bacteriophages by coun-
ter-selecting unmodified phages with wild-type target
sequences [119]. In vitro assembly of large constructs
has also been made possible with techniques such as
Gibson assembly [120], which enzymatically stitches
together DNA fragments with overlapping homology,
thus allowing for insertions of heterologous DNA and
site-directed mutagenesis using PCR. Moreover, trans-
formation of overlapping fragments into yeast in conjunc-
tion with a compatible yeast artificial chromosome leads
to in vivo recombination-based assembly of large con-
structs [121,122]. Genomes can be assembled with modi-
fications or be modified post-assembly in yeast, where
they are non-toxic to the host, and then purified and
rebooted in bacteria to produce engineered phage pro-
geny. Current DNA synthesis technology, in concert with
in vivo and in vitro recombination, also permits de novo
chemical synthesis of bacteriophage genomes. Smith et al.
[123] utilized this approach to synthesize, clone, and
produce infectious particles of the 5386 bp phage
FX174, and a similar scaled-up approach has created
the first bacterial cell with a synthetic genome of
1.1 Mb [124]. By rendering bacteriophages genetically
accessible, synthetic biology can permit more precise
studies of their underlying biology and inspire creation
of novel therapeutic agents.
Refactoring and genome stability
Despite advances in rational engineering of bacterio-
phages, tampering with systems finely tuned by evolu-
tion can lead to fitness defects [125]. For example,
roughly 30% of the genome of the bacteriophage T7
was ‘refactored,’ a process whereby genes and their
respective regulatory elements were separated into dis-
tinct modules to permit systematic analysis and control
[126]. The refactored genome produced viable bacterio-
phage, albeit with significantly reduced fitness. Multiple
rounds of in vitro evolution restored wild-type viability
at the expense of some of the design elements, implying
that rational design can be coupled with evolution to
ensure the creation of robust biological systems [127].
Similarly, the evolutionary stability of a T7 phage
engineered to infect encapsulated E. coli by producing
a capsule-degrading endosialidase as an exoenzyme was
investigated in vitro [128]. While the engineered phage
permitted replication in the encapsulated strain, the
benefit conferred by endosialidase production was
shared by wild-type, non-producing ‘cheater’ phages,
which could quickly outcompete  the engineered viruses
due to their higher fitness. Although these studies pointwww.sciencedirect.com to the fragility of current synthetic biology efforts,
bacteriophage-based systems can serve as an excellent
platform to understand the constraints placed on syn-
thetic genetic circuits by evolution and inform future
designs.
Conclusions
Bacteriophages and functional components derived
from their genomes have long been powerful tools that
have allowed us to understand basic biological processes
and that sparked the field of molecular biology. Mount-
ing concerns over the spread of multidrug-resistant
bacterial pathogens, as well as the development of
enabling technologies from synthetic biology, have
resulted in the resurgence of studies involving these
highly evolved and specialized viruses. Recent efforts
have made strides in engineering phages with modified
properties, endowing entirely new functions, and deriv-
ing repurposed parts for the study, detection, and treat-
ment of infectious diseases (Figure 4). As our ability to
engineer phages through genome synthesis and modi-
fication continues to improve, we will be able to further
leverage these finely tuned products of evolution that
constitute the most numerous biological entities known
to man.
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